Charcot-Marie-Tooth disease

  • CLN-PXT3003-06_PREMIER: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A)
  • MetaDLM_CMT2A: Metabolomic exploration of lipid metabolism dysregulation in Mitofusin 2-related Charcot-Marie-Tooth disease type 2A (CMT2A)





Pathology CMT1A CMT2A
Intervention PXT3003
Principal investigator Tanya Stojkovic Tanya Stojkovic
Sponsor Pharnext CHU Angers
Study status Active Active
Recruitment status Completed Ongoing
Population Adult Adult
   + infos on clinical + infos sur


Contact :